Lantheus HoldingsLNTH +0.88%82 Interest Coverage is 16.72 as of Mar. 2026, which is 278% above its 10-year median of 4.42. GuruFocus rates LNTH with a GF Score™ of 82/100 and a GF Value™ of $90.85 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 686 Drug Manufacturers companies, Lantheus Holdings ranks better than 53.5% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Lantheus Holdings's
Operating Income
for the
three
months ended in Mar. 2026 was $81 Mil. Lantheus Holdings's Interest Expense for the
three
months ended in Mar. 2026 was $-5 Mil.
Lantheus Holdings's interest coverage for the quarter that ended in Mar. 2026 was 16.72.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Lantheus Holdings's Interest Coverage or its related term are showing as below:
LNTH'
s Interest Coverage Range Over the Past 10 Years
Min: 1.89 Med: 4.42 Max: 22.81
Current: 14.64
LNTH's Interest Coverage is ranked better than 53.5% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.725
vs LNTH: 14.64
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Lantheus Holdings Interest Coverage Related Terms
Lantheus Holdings Interest Coverage Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LNTH vs LQDA, HIMS, AMRX: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a Interest Coverage of 16.72 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lantheus Holdings and its competitors. This is 278% above median its historical median of 4.42. Over the past decade, Lantheus Holdings' Interest Coverage has ranged from 1.89 to 22.81. According to the industry distribution chart, Lantheus Holdings ranks #319 out of 686 companies in the Drug Manufacturers industry, placing it in the top 46.5%.
Is Lantheus Holdings' Interest Coverage too high?
Lantheus Holdings' current Interest Coverage of 16.72 is 278% above median its 10-year median of 4.42. Over the past 10 years, this metric has ranged from a low of 1.89 to a high of 22.81. The Drug Manufacturers industry median Interest Coverage is 12.73. Lantheus Holdings' value of 16.72 is 31.4% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #319 out of 686 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lantheus Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Interest Coverage compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #319 out of 686 companies for Interest Coverage. This puts Lantheus Holdings in the upper half of its industry. The industry median Interest Coverage is 12.73. Lantheus Holdings' value of 16.72 is 31.4% above this benchmark. Historically, Lantheus Holdings' own Interest Coverage has ranged from 1.89 to 22.81 over the past decade. While the company's 10-year median is 4.42 vs. the industry median of 12.73, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current Interest Coverage of 16.72 is 31.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current Interest Coverage is 16.72, which is 278% above median its own 10-year median of 4.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.85, compared to a current price of $109.89 — trading 21% above its estimated fair value. The current Interest Coverage is 16.72, which is 278% above median its 10-year median of 4.42 and 31.4% above the Drug Manufacturers industry median of 12.73. Lantheus Holdings' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Interest Coverage is 16.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $109.89 is trading 21% above its estimated GF Value™ of $90.85.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for LNTH:
Interest Coverage: 16.72 (278% above median its 10-year median of 4.42)
GF Value™: $90.85 vs. price of $109.89 (21% above fair value)
Industry Position: 31.4% above the Drug Manufacturers median (#319 of 686)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
82GF Score
Get the complete analysis for LNTH
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
